Lobe Sciences Ltd. (LOBE.CN)
| Previous Close | 0.0200 |
| Open | 0.0200 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's Range | 0.0200 - 0.0200 |
| 52 Week Range | 0.0100 - 0.0300 |
| Volume | |
| Avg. Volume | 20,041 |
| Market Cap | 3.294M |
| Beta (5Y Monthly) | 2.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | Jul 30, 2024 - Aug 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireLobe Sciences Announces Update
VANCOUVER, British Columbia, June 04, 2024--Company Exploring Alternative Value Creation Opportunities; $500,000 Convertible Note Issued; Balance Sheet Strengthened; AGM Set for 22 July 2024
Business WireWesley Ramjeet to Join Lobe Sciences’ Board of Directors, Bringing Decades of Strategic Financial Expertise
VANCOUVER, British Columbia, June 03, 2024--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced that Wesley Ramjeet has agreed to join its Board of Directors in the coming months. With over two decades of experience as a mission-focused leader, Ramjeet is recognized for his exceptional ability to navigate complex transactions including acquisitions, initial publi
Business WireLobe Sciences Announces Frederick D. Sancilio Ph.D. to Join Board of Directors
VANCOUVER, British Columbia, May 31, 2024--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced that Frederick D. Sancilio Ph.D. has agreed to join its Board of Directors. Dr. Sancilio brings over four decades of successful experience in pharmaceutical sciences and biopharmaceutical research, further strengthening Lobe Sciences' commitment to pioneering advancemen
